Abstract
Treatment with antiproliferative drugs via coated stents appears to be a promising approach to both mechanically remodel target lesions and biologically reduce neointimal hyperplasia. Drug-eluting stents can maximize local drug effects and minimize the potential for systemic toxic effects. The purpose of this review is to describe the effects of a lipophilic microtubular inhibitor, paclitaxel, a strong antiproliferative agent under clinical investigation, and to define the vascular response to taxol-based eluting stents by intravascular ultrasound.
MeSH terms
-
Angiogenesis Inhibitors / pharmacology*
-
Angiogenesis Inhibitors / therapeutic use*
-
Blood Vessel Prosthesis Implantation
-
Cardiac Surgical Procedures
-
Clinical Trials as Topic
-
Coated Materials, Biocompatible / pharmacology*
-
Coated Materials, Biocompatible / therapeutic use*
-
Coronary Restenosis / diagnostic imaging
-
Coronary Restenosis / prevention & control
-
Humans
-
Paclitaxel / pharmacology*
-
Paclitaxel / therapeutic use*
-
Reproducibility of Results
-
Stents*
-
Ultrasonography, Interventional
Substances
-
Angiogenesis Inhibitors
-
Coated Materials, Biocompatible
-
Paclitaxel